ALLO-329 for Autoimmune Diseases
This study is testing a new cell therapy called ALLO-329 for adults with certain autoimmune diseases like lupus (Systemic Lupus Erythematosus), muscle inflammation (Idiopathic Inflammatory Myopathy), and hardened skin (Systemic Sclerosis). ALLO-329 is a type of CAR T-cell therapy, which uses specially modified immune cells to target specific cells in your body. Before receiving ALLO-329, you would also receive chemotherapy drugs, Cyclophosphamide and Fludarabine. The main goal is to see how safe ALLO-329 is and if it causes any serious side effects. Researchers also want to see if it shows early signs of helping with these conditions. The study is currently unclear on its recruitment status and plans to enroll 66 participants aged 18 to 74 years.
- Study design
- This is a first-in-human, single-arm, open-label study, meaning all participants receive the same treatment and both you and the researchers will know what treatment you are getting. It plans to enroll 66 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety will be monitored for up to 60 months (5 years) after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
At a glance
Conditions
Where it's being run
15 sites across 14 statesStudy leadership
- Allogene Study Director · STUDY_DIRECTOR · Allogene Therapeutics, Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of Dose Limiting toxicities (DLTs) and Other Safety ParametersUp to 60 months
The incidence of dose limiting toxicities (DLTs) and other safety parameters (including but not limited to treatment emergent adverse events \[AEs\], serious adverse events \[SAEs\], and clinical laboratory abnormalities)